Ceftolozane/tazobactam: place in therapy

On Behalf Of Isgri-Sita (Italian Study Group On Resistant Infections Of The Società Italiana Terapia Antinfettiva)

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Introduction: Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A trial on hospital-acquired pneumonia is ongoing. Areas covered: The place in therapy of C/T is delineated by addressing the following main topics: (i) antimicrobial properties; (ii) pharmacological properties; (iii) results of clinical studies. Expert commentary: C/T is approved for cIAI and cUTI. However, the drug has a special value for clinicians in any kind of infectious localization for two main reasons. The first is that C/T is especially valuable in suspected or documented severe infections due to MDR P. aeruginosa, which is not a rare occurrence in many countries. The second is that C/T may provide an alternative to carbapenems for the treatment of infections caused by ESBL-producers, thus allowing a carbapenem-sparing strategy. Reporting of off-label use is mandatory to increase the body of evidence and the clinicians’ confidence in using it for indications other than cIAI and cUTI.

Original languageEnglish
Pages (from-to)307-320
Number of pages14
JournalExpert Review of Anti-Infective Therapy
Volume16
Issue number4
DOIs
Publication statusPublished - Apr 3 2018

Fingerprint

Intraabdominal Infections
Urinary Tract Infections
Carbapenems
Therapeutics
Pharmaceutical Preparations
Off-Label Use
Ceftazidime
Enterobacteriaceae
Cephalosporins
Infection
tazobactam drug combination ceftolozane
Pneumonia
Pharmacology
Anti-Bacterial Agents

Keywords

  • Antimicrobial resistance
  • carbapenem-sparing
  • ceftolozane
  • Enterobacteriaceae
  • ESBL
  • MDR
  • Pseudomonas
  • tazobactam

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

On Behalf Of Isgri-Sita (Italian Study Group On Resistant Infections Of The Società Italiana Terapia Antinfettiva) (2018). Ceftolozane/tazobactam: place in therapy. Expert Review of Anti-Infective Therapy, 16(4), 307-320. https://doi.org/10.1080/14787210.2018.1447381

Ceftolozane/tazobactam : place in therapy. / On Behalf Of Isgri-Sita (Italian Study Group On Resistant Infections Of The Società Italiana Terapia Antinfettiva).

In: Expert Review of Anti-Infective Therapy, Vol. 16, No. 4, 03.04.2018, p. 307-320.

Research output: Contribution to journalReview article

On Behalf Of Isgri-Sita (Italian Study Group On Resistant Infections Of The Società Italiana Terapia Antinfettiva) 2018, 'Ceftolozane/tazobactam: place in therapy', Expert Review of Anti-Infective Therapy, vol. 16, no. 4, pp. 307-320. https://doi.org/10.1080/14787210.2018.1447381
On Behalf Of Isgri-Sita (Italian Study Group On Resistant Infections Of The Società Italiana Terapia Antinfettiva). Ceftolozane/tazobactam: place in therapy. Expert Review of Anti-Infective Therapy. 2018 Apr 3;16(4):307-320. https://doi.org/10.1080/14787210.2018.1447381
On Behalf Of Isgri-Sita (Italian Study Group On Resistant Infections Of The Società Italiana Terapia Antinfettiva). / Ceftolozane/tazobactam : place in therapy. In: Expert Review of Anti-Infective Therapy. 2018 ; Vol. 16, No. 4. pp. 307-320.
@article{4d3340664ff14ea28389614b13521fbe,
title = "Ceftolozane/tazobactam: place in therapy",
abstract = "Introduction: Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A trial on hospital-acquired pneumonia is ongoing. Areas covered: The place in therapy of C/T is delineated by addressing the following main topics: (i) antimicrobial properties; (ii) pharmacological properties; (iii) results of clinical studies. Expert commentary: C/T is approved for cIAI and cUTI. However, the drug has a special value for clinicians in any kind of infectious localization for two main reasons. The first is that C/T is especially valuable in suspected or documented severe infections due to MDR P. aeruginosa, which is not a rare occurrence in many countries. The second is that C/T may provide an alternative to carbapenems for the treatment of infections caused by ESBL-producers, thus allowing a carbapenem-sparing strategy. Reporting of off-label use is mandatory to increase the body of evidence and the clinicians’ confidence in using it for indications other than cIAI and cUTI.",
keywords = "Antimicrobial resistance, carbapenem-sparing, ceftolozane, Enterobacteriaceae, ESBL, MDR, Pseudomonas, tazobactam",
author = "{On Behalf Of Isgri-Sita (Italian Study Group On Resistant Infections Of The Societ{\`a} Italiana Terapia Antinfettiva)} and Giacobbe, {Daniele Roberto} and Matteo Bassetti and {De Rosa}, {Francesco Giuseppe} and {Del Bono}, Valerio and Grossi, {Paolo Antonio} and Francesco Menichetti and Federico Pea and Rossolini, {Gian Maria} and Mario Tumbarello and Pierluigi Viale and Claudio Viscoli",
year = "2018",
month = "4",
day = "3",
doi = "10.1080/14787210.2018.1447381",
language = "English",
volume = "16",
pages = "307--320",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Ceftolozane/tazobactam

T2 - place in therapy

AU - On Behalf Of Isgri-Sita (Italian Study Group On Resistant Infections Of The Società Italiana Terapia Antinfettiva)

AU - Giacobbe, Daniele Roberto

AU - Bassetti, Matteo

AU - De Rosa, Francesco Giuseppe

AU - Del Bono, Valerio

AU - Grossi, Paolo Antonio

AU - Menichetti, Francesco

AU - Pea, Federico

AU - Rossolini, Gian Maria

AU - Tumbarello, Mario

AU - Viale, Pierluigi

AU - Viscoli, Claudio

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Introduction: Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A trial on hospital-acquired pneumonia is ongoing. Areas covered: The place in therapy of C/T is delineated by addressing the following main topics: (i) antimicrobial properties; (ii) pharmacological properties; (iii) results of clinical studies. Expert commentary: C/T is approved for cIAI and cUTI. However, the drug has a special value for clinicians in any kind of infectious localization for two main reasons. The first is that C/T is especially valuable in suspected or documented severe infections due to MDR P. aeruginosa, which is not a rare occurrence in many countries. The second is that C/T may provide an alternative to carbapenems for the treatment of infections caused by ESBL-producers, thus allowing a carbapenem-sparing strategy. Reporting of off-label use is mandatory to increase the body of evidence and the clinicians’ confidence in using it for indications other than cIAI and cUTI.

AB - Introduction: Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A trial on hospital-acquired pneumonia is ongoing. Areas covered: The place in therapy of C/T is delineated by addressing the following main topics: (i) antimicrobial properties; (ii) pharmacological properties; (iii) results of clinical studies. Expert commentary: C/T is approved for cIAI and cUTI. However, the drug has a special value for clinicians in any kind of infectious localization for two main reasons. The first is that C/T is especially valuable in suspected or documented severe infections due to MDR P. aeruginosa, which is not a rare occurrence in many countries. The second is that C/T may provide an alternative to carbapenems for the treatment of infections caused by ESBL-producers, thus allowing a carbapenem-sparing strategy. Reporting of off-label use is mandatory to increase the body of evidence and the clinicians’ confidence in using it for indications other than cIAI and cUTI.

KW - Antimicrobial resistance

KW - carbapenem-sparing

KW - ceftolozane

KW - Enterobacteriaceae

KW - ESBL

KW - MDR

KW - Pseudomonas

KW - tazobactam

UR - http://www.scopus.com/inward/record.url?scp=85045662944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045662944&partnerID=8YFLogxK

U2 - 10.1080/14787210.2018.1447381

DO - 10.1080/14787210.2018.1447381

M3 - Review article

C2 - 29493397

AN - SCOPUS:85045662944

VL - 16

SP - 307

EP - 320

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 4

ER -